BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Abelacimab readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Abelacimab\, from ClinicalTrials.gov esti
 mates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05712200-11264@assetmemo.bio
DTSTAMP:20261121T004534Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Abelacimab: Phase 3 readout est. (NCT05712200)
DESCRIPTION:Abelacimab\, phase 3.\nStudy: Study to evaLuate the effIcacy an
 d Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who 
 Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)\nEsti
 mated primary completion: 30 December 2027. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/abelacimab#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT05712200
URL:https://assetmemo.bio/drug/abelacimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07739888-11264@assetmemo.bio
DTSTAMP:20261121T004534Z
DTSTART;VALUE=DATE:20301230
DTEND;VALUE=DATE:20301231
SUMMARY:Abelacimab: Phase 3 readout est. (NCT07739888)
DESCRIPTION:Abelacimab\, phase 3.\nStudy: Study to Evaluate the effIcacy an
 d Safety of Abelacimab in High-risk Patients With Atrial Fibrillation Who 
 Have Been Deemed Unsuitable for Oral Anticoagulation\nEstimated primary co
 mpletion: 30 December 2030. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/abelacimab#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT07739888
URL:https://assetmemo.bio/drug/abelacimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
